JD Ziegler - ViewRay Chief Officer
| VRAYDelisted Stock | USD 0.04 0 5.67% |
Insider
JD Ziegler is Chief Officer of ViewRay
| Age | 50 |
| Phone | 440 703 3210 |
| Web | https://www.viewray.com |
ViewRay Management Efficiency
The company has return on total asset (ROA) of (0.2529) % which means that it has lost $0.2529 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0891) %, meaning that it created substantial loss on money invested by shareholders. ViewRay's management efficiency ratios could be used to measure how well ViewRay manages its routine affairs as well as how well it operates its assets and liabilities.ViewRay currently holds 86.4 M in liabilities with Debt to Equity (D/E) ratio of 0.54, which is about average as compared to similar companies. ViewRay has a current ratio of 2.98, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ViewRay's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Ehab Esmail | Orthofix Medical | 52 | |
| John Ordway | Sight Sciences | N/A | |
| Gregory Davault | Axogen Inc | 56 | |
| BA Chemistry | Orthofix Medical | 63 | |
| Marna Borgstrom | Artivion | 67 | |
| Blake Gurfein | Tivic Health Systems | 40 | |
| Agnes Lee | Inogen Inc | N/A | |
| Scott Capps | Artivion | 53 | |
| Michelle Scharfenberg | Avanos Medical | N/A | |
| Robin Wagge | Delcath Systems | N/A | |
| Sanjay Ahuja | Tivic Health Systems | N/A | |
| Mark Quick | Orthofix Medical | N/A | |
| Rochelle Maney | Artivion | 45 | |
| Andre Marquette | Neuropace | N/A | |
| Daniel Bevevino | Artivion | 61 | |
| Matthew Pigeon | Inogen Inc | N/A | |
| Anthony Dias | Delcath Systems | 57 | |
| Bart Bracy | Anika Therapeutics | N/A | |
| Anne Nunes | Anika Therapeutics | 54 | |
| John Liu | Sight Sciences | N/A | |
| Stacie Rodgers | Sight Sciences | N/A | |
Management Performance
| Return On Equity | -1.09 | |||
| Return On Asset | -0.25 |
ViewRay Leadership Team
Elected by the shareholders, the ViewRay's board of directors comprises two types of representatives: ViewRay inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ViewRay. The board's role is to monitor ViewRay's management team and ensure that shareholders' interests are well served. ViewRay's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ViewRay's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert McCormack, Chief Officer | ||
| Robert Fuchs, Chief Officer | ||
| Zachary Stassen, Chief Officer | ||
| James Dempsey, Chief Scientific Officer, Director | ||
| Martin MD, Chief Officer | ||
| JD Ziegler, Chief Officer | ||
| Karen Hackstaff, VP Marketing | ||
| Scott Drake, CEO Pres | ||
| Matt Harrison, Director Relations | ||
| Drew Hill, VP Devel |
ViewRay Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ViewRay a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.25 | |||
| Profit Margin | (1.04) % | |||
| Operating Margin | (1.02) % | |||
| Current Valuation | 11.47 M | |||
| Shares Outstanding | 183.4 M | |||
| Shares Owned By Insiders | 17.36 % | |||
| Shares Owned By Institutions | 74.60 % | |||
| Number Of Shares Shorted | 5.47 M | |||
| Price To Earning | (5.47) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in ViewRay Stock
If you are still planning to invest in ViewRay check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ViewRay's history and understand the potential risks before investing.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |